好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Defining Clinically Meaningful Change on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS)
Movement Disorders
P1 - Poster Session 1 (5:30 PM-6:30 PM)
10-043

To enhance interpretation of change on the composite Unified Huntington’s Disease Rating Scale (cUHDRS).

The cUHDRS was developed to assess disease progression in early-to-moderate manifest Huntington’s disease (HD). It consists of four assessments: Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test and Stroop Word Reading. Composite endpoints can be difficult to interpret; thus, qualitative and quantitative evidence was generated to aid interpretation of cUHDRS clinically meaningful change.

Qualitative evidence was reviewed to identify the importance of the concepts measured by each individual scale. This included a targeted literature review and patient/caregiver interviews. To better understand the relative contribution of each scale, meaningful change estimates were produced for each constituent measure, using a 1-category worsening on the CGI-S over 12 months (REGISTRY), and was compared to the denominators of the z-scores used in the cUHDRS scoring algorithm. To demonstrate how the cUHDRS score relates to daily functional ability, cUHDRS scores across manifest HD patients were split into deciles and the proportion of patients achieving each item on the Functional Assessment was calculated (ENROLL-HD). Finally, meaningful within-patient change estimates (over 12 months) were produced for the cUHDRS using 1-category worsening on CGI-S (REGISTRY) and a decline of 10 points on Independence Scale (ENROLL-HD) as anchors.

Qualitative evidence highlights the importance to patients and their families of cognitive and motor impairments, and loss of daily functional ability resulting from HD. Meaningful change estimates for the individual scales have a similar ratio to the denominators used to create z-scores. A strong relationship between cUHDRS and functional ability was demonstrated. Triangulation of meaningful change estimates produced a value of 1.2.

The cUHDRS score uses logical weighting for its constituent scales and produces a score that associates strongly with functional ability. A worsening of 1.2 points can be considered clinically meaningful.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
Scott Schobel Scott Schobel has received personal compensation for serving as an employee of F. Hoffman-La Roche Ltd.
Jeffrey D. Long Jeffrey Long has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Triplet. Jeffrey Long has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vacinnex. Jeffrey Long has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave. Jeffrey Long has received personal compensation in the range of $0-$499 for serving as a Consultant for PTC. Jeffrey Long has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Jeffrey Long has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Jeffrey Long has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Jeffrey Long has received research support from NIH DSMB.
Blair Leavitt, MD (University of British Columbia) Dr. Leavitt has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Incisive Genetics. Dr. Leavitt has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Leavitt has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Design TX. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReMix Tx. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sintetica. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Triplet Tx. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Leavitt has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Incisive Genetics. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Huntington's Disease. Dr. Leavitt has stock in Incisive Genetics. Dr. Leavitt has stock in SRNAlytics. The institution of Dr. Leavitt has received research support from CIHR. The institution of Dr. Leavitt has received research support from HSC. The institution of Dr. Leavitt has received research support from Brain Canada. The institution of Dr. Leavitt has received research support from NMIN. Dr. Leavitt has received intellectual property interests from a discovery or technology relating to health care.
Sarah J. Tabrizi, MD, PhD Sarah J. Tabrizi, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for F. Hoffmann-La Roche Ltd. Sarah J. Tabrizi, MD, PhD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech.